<DOC>
	<DOCNO>NCT01722812</DOCNO>
	<brief_summary>The purpose exploratory study investigate clinical efficacy cromoglicate cream compare cream vehicle treatment itch psoriasis</brief_summary>
	<brief_title>Cromoglicate Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Cromolyn Sodium</mesh_term>
	<criteria>Signed informed consent obtain Age 18 year Either sex Any race ethnicity Attending hospital outpatient clinic private practice dermatologist Clinical diagnosis stable plaque psoriasis least 6 month symmetric distribution Two treatment area symmetrical distribution correspond 23 % BSA include least one itchy psoriasis plaque Itchy psoriasis intend treatment area least 40mm Visual Analogue Scale ( VAS ) maximum difference 10mm visual analogue scale two treatment area Disease severity grade mild , moderate severe accord Physician 's global assessment ( PGA ) disease severity psoriasis plaque two treatment area . The disease severity must treatment area Systemic treatment biological therapy , whether market , possible effect psoriasis vulgaris within follow time period prior randomisation : etanercept within 4 week prior randomisation adalimumab , infliximab within 8 week prior randomisation ustekinumab within 16 week prior randomisation product 4 weeks/5 halflives ( whichever longer ) Systemic treatment therapy possible effect psoriasis vulgaris ( e.g. , corticosteroid , retinoids , methotrexate , ciclosporin , fumaric acid derivative , immunosuppressant ) within 4 week prior randomization Any topical treatment treatment area ( except emollient ) within 2 week prior randomisation . Treatment therapy , whether market , possible effect itch within follow time period prior randomisation : antihistamins within 1 week prior randomisation gabapentin within 4 week prior randomisation Subjects receive treatment nonmarketed drug substance ( i.e . drug yet make available clinical use follow registration ) within 4week period prior randomisation longer , class substance require longer treatment free period define exclusion criterion 1 biological treatment PUVA Grenz ray therapy within 4 week prior randomisation . UVB therapy within 2 week prior randomisation Planned initiation , change concomitant medication could affect psoriasis vulgaris ( e.g. , beta blocker , ACE inhibitor , antimalaria drug , lithium ) within 2 week prior randomisation Subjects current participation interventional clinical trial Subjects follow condition present treatment area : viral ( e.g . herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , acne vulgaris , atrophic skin , stria atrophicae , fragility skin vein , icthyosis , ulcer wound Other inflammatory skin disorder ( e.g . seborrhoeic dermatitis contact dermatitis ) treatment area may confound evaluation psoriasis Subjects history serious allergy , allergic skin rash sensitivity component investigational product formulation test Known suspect severe renal insufficiency severe hepatic disorder Current diagnosis erythrodermic , exfoliative , guttate pustular psoriasis Planned exposure sun study may affect psoriasis vulgaris ( i.e. , normal lifestyle outdoor activity permit deliberate exposure sunlight artificial ultraviolet light avoid ) Subjects previously randomise trial Not exclusion criterion list due limited space</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>